Burden of Parkinsonism: A population-based study

Movement Disorders

Volumn 18, Issue 3, 2003, Pages 313-319

  Guttman, Mark ^a   Slaughter, Pamela M ^b   Theriault, Marc Erick ^b   DeBoer, Donald P ^b   Naylor, C David ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Epidemiology; Health services research; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGE; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; MALE; MEDICAL FEE; PARKINSON DISEASE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIETY;

ADULT; AGED; CANADA; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PREVALENCE;

EID: 0037357259     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10333     Document Type: Article

References (26)

1. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998;339:1044-1053.
2. Lang AE, Lozano AM. Parkinson's disease: second of two parts. N Engl J Med 1998;339:1130-1143.
3. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacological treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000;57:953-962.
4. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family and the individual. J Am Geriatr Soc 1997;45:844-849.
5. Singer E. Social costs of Parkinson's disease. J Chronic Dis 1973; 26:243-254.
6. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Pharmacoeconomics 1997;12:486-498.
7. Dodel RC, Singer M, Kohne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
8. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared to controls in a large cohort study. Neurology 2001;57:2278-2282.
9. Zhang Z, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208.
10. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz C, Pilgrim DM, Evans DA. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;71-76.
11. Snow BJ, Wiens M, Hertzman C, Calne DB. A community survey of Parkinson's disease. Can Med Assoc J 1989;141:418-422.
12. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ 2000;321:21-22.
13. Kuopio A-M, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999;52:302-308.
14. Sutcliffe RLG, Meara JR. Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995;92:443-450.
15. Caradoc-Davies TH, Weatherall M, Dixon GS, Carodoc-Davies G, Hantz P. Is the prevalence of Parkinson's disease in New Zealand really changing? Acta Neurol Scand 1992;86:40-44.
16. deRijk MC, Breteler MMB, Graveland A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;2143-2146.
17. Svenson LW, Platt GH, Woodhead SE. Geographic variations in the prevalence rates of Parkinson's disease in Alberta. Can J Neurol Sci 1993;20:307-311.
18. Nobrega FT, Glattre E, Kurland LT, Okazaki H. Comments on the epidemiology of Parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette J-R, editors. Progress in neuro-genetics. Amsterdam: Excerpta Medica; 1967. p. 474-485.
19. Rajput AH, Offord KP, Beard M, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-282.
20. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson's disease. Mov Disord 1998;13:249-254.
21. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-413.
22. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
23. Williams JI, Young W. Patterns of health care in Ontario: the ICES practice atlas. 2nd ed. In: Goel V, Anderson GM, Fooks C, Iron K, Naylor CD, editors. Ottawa: Canadian Medical Association; 1996. p. 339-345.
24. Efron E, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993. p. 168-177.
25. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13:175-178.
26. Moghal S, Rajput AH, Meleth R, D'Arcy C, Rajput R. Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology 1995;14:297-300.